BMO Capital Markets Issues Pessimistic Forecast for Disc Medicine (NASDAQ:IRON) Stock Price

Disc Medicine (NASDAQ:IRON) had its price objective reduced by stock analysts at BMO Capital Markets from $120.00 to $100.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ target price would indicate a potential upside of 67.14% from the company’s previous close.

Other equities analysts have also issued research reports about the company. UBS Group reissued an “overweight” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Raymond James Financial reaffirmed a “market perform” rating on shares of Disc Medicine in a report on Thursday, January 15th. Morgan Stanley reissued an “overweight” rating and set a $120.00 price objective on shares of Disc Medicine in a report on Thursday, January 8th. Wells Fargo & Company boosted their target price on shares of Disc Medicine from $91.00 to $109.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, TD Cowen reissued a “buy” rating on shares of Disc Medicine in a research note on Friday, December 19th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $112.82.

Disc Medicine Stock Performance

NASDAQ:IRON opened at $59.83 on Tuesday. The stock has a market capitalization of $2.26 billion, a P/E ratio of -11.29 and a beta of 0.88. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05. Disc Medicine has a 1 year low of $30.82 and a 1 year high of $99.50. The firm has a 50 day moving average of $78.93 and a 200-day moving average of $75.24.

Insider Buying and Selling

In related news, CEO John D. Quisel sold 40,000 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $93.05, for a total transaction of $3,722,000.00. Following the sale, the chief executive officer owned 171,828 shares of the company’s stock, valued at approximately $15,988,595.40. This trade represents a 18.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kevin Bitterman sold 754 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $91.47, for a total value of $68,968.38. Following the completion of the transaction, the director directly owned 14,013 shares of the company’s stock, valued at approximately $1,281,769.11. The trade was a 5.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 245,470 shares of company stock valued at $22,425,170. Insiders own 3.64% of the company’s stock.

Hedge Funds Weigh In On Disc Medicine

Institutional investors have recently modified their holdings of the business. TimesSquare Capital Management LLC acquired a new position in Disc Medicine during the third quarter valued at approximately $12,038,000. Y Intercept Hong Kong Ltd raised its stake in shares of Disc Medicine by 361.4% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 43,287 shares of the company’s stock worth $2,860,000 after purchasing an additional 33,905 shares in the last quarter. Atle Fund Management AB boosted its holdings in shares of Disc Medicine by 85.3% in the 3rd quarter. Atle Fund Management AB now owns 45,690 shares of the company’s stock valued at $3,019,000 after buying an additional 21,038 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Disc Medicine by 11.1% in the second quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company’s stock valued at $44,678,000 after buying an additional 84,278 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new position in Disc Medicine during the third quarter worth $689,000. Institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.